Age Adapted Induction and Intensified Consolidation Therapy in Acute Myelogenous Leukemia

Publisher Website
Google Scholar
Abstract
52 patients entered a study for remission induction and intensified consolidation in AML. Group I (age < 50 years) received a combination of DNR, ara-C and VP16-213 for induction and early consolidation and HDara-C/DNR for late consolidation. Of 34 evaluable patients (25 first diagnosis, 9 first relapse), 27 achieved CR. 13 patients received 1-2 courses of HDara-C/DNR. Toxic symptoms of HDara-C/DNR were severe myelosuppression, infections, skin reactions, diarrhea and hepatotoxicity. CNS toxicity was not observed. 2 patients died from infection. The duration of granulocytopenia ( < 500/µl) was 7-43 days (range) and of thrombocytopenia ( < 25,000/ µl) 5-34 days (range). Patients of group II (age > 50 years) received a modified regimen with reduced toxicity. Their number is too small for evaluation as yet.